Trial Profile
A phase I/II study of dasatinib and dacarbazine in patients with metastatic melanoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jul 2012
Price :
$35
*
At a glance
- Drugs Dacarbazine (Primary) ; Dasatinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov
- 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2012 Planned end date changed from 1 Jul 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.